Avoid Anti-HER2 Cancer Therapies During Pregnancy

Women with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates.

Related Keywords

France ,Paris ,France General ,Jean Philippe Spano ,Paul Gougis ,Daiichi Sakyo ,Novartis ,World Health Organization ,Astrazeneca ,Institut Curie Centre De Recherche ,Pfizer ,Breast Cancer ,Alignant Breast Neoplasm ,Pregnancy ,Biologic Therapy ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Her2 Positive Breast Cancer ,Her2 Breast Cancer ,Targeted Therapy ,Cancer ,Alignant Neoplasia ,Arcinoma ,Breast ,Newborn ,Neonate ,Malignant Kidney Neoplasm ,Kidney Cancer ,Renal Cell Cancer ,Enal Cell Ca ,